News Releases

$

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Hero Chart
FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 22, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference November 30, 2021 Format: Fireside Chat
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 17, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) for $110 million .
... Read More
Additional Formats
- U.S. commercial launch underway following U.S. FDA approval of LIVMARLI™ (maralixibat) oral solution - Six-year analysis showing significant improvement in event-free survival with LIVMARLI compared to natural history cohort (p
... Read More
Additional Formats
- Results demonstrate statistically significant improvement in six-year event-free survival (p
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 8, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will report financial results for the quarter ended September 30, 2021 on Monday, November 15, 2021 . That same day, Mirum will host a conference call and audio webcast
... Read More
Additional Formats
- LIVMARLI (maralixibat) late-breaker oral presentation on a six-year event-free survival analysis in Alagille syndrome compared to a natural history cohort; selected for Best of the Liver Meeting - Second late-breaker presentation to highlight predictors of event-free survival in patients treated
... Read More
Additional Formats
- Maralixibat data demonstrate four-year durable and clinically meaningful improvements across multiple cholestasis parameters including pruritus. FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 1, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that
... Read More
Additional Formats
Mirum to host an investor call on September 29, 2021 at 4:30 p.m. ET FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 29, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI™
... Read More
Additional Formats
Partnership leverages Takeda’s leadership in rare disease, gastroenterology, and hepatology to advance maralixibat in a major market FOSTER CITY, Calif. & OSAKA, Japan --(BUSINESS WIRE)--Sep. 21, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Takeda Pharmaceutical Company Limited (
... Read More
Additional Formats
- Marketing Authorization Application for treatment of cholestatic disease in Alagille syndrome submitted. - Natural history analysis shows significant improvement in event-free survival and transplant-free survival. - PFIC regulatory strategy in Europe to focus on results of MARCH-PFIC Phase 3
... Read More
Additional Formats